查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1499967

全球多發性硬化症市場評估：依 MS 類型、藥物類別、診斷、給藥途徑、最終用戶、地區、機會、預測（2017-2031 年）

Multiple Sclerosis Market Assessment, By Type of MS, By Drug Class, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球多發性硬化症市場規模預計將從 2023 年的 271.2 億美元增至 2031 年的 378.1 億美元，預計 2024-2031 年的複合年增長率為 4.24%。該市場受到多種因素的影響，包括政府舉措、技術進步、對免疫抑制劑不斷增長的需求、復發緩解性疾病的治療以及對研發的日益關注。

世界各國政府正在採取多項措施來指導和教育人們如何治療多發性硬化症，並提高公眾對該疾病的認識。這些措施有助於加速全球多發性硬化症市場的擴張並支持區域發展。基於人工智慧的工具越來越多地被使用，擾亂了全球多發性硬化症市場。這些工具徹底改變了新藥的開發，並改變了全球多發性硬化症市場。研究能力的增強正在推動治療多發性硬化症的先進精準藥物的開發。

全球多發性硬化症市場的成長受到治療各種類型多發性硬化症的免疫抑製藥物需求不斷增長的影響。這些藥物在改變免疫系統反應、減少發炎和延緩老化過程中發揮作用。全球多發性硬化症市場受到治療復發緩解型多發性硬化症藥物需求的增加所推動。多家公司致力於開發客製化治療方法，透過解決與這種疾病相關的特定課題和症狀來滿足需求。全球多發性硬化症市場的領導者正在優先考慮透過研究和開發改善症狀治療，以改善疾病的進展。這些努力正在推動疾病管理創新技術的發展。

例如，2024年5月，韋恩州立大學醫學院分子醫學和遺傳學中心教授兼副主任、兒科和神經病學教授Alexander Gow博士宣佈，他被診斷出可能患有多發性硬化症為了找出原因，我們從NMSS（National Multiple Sclerosis Society）獲得了為期三年的研究經費644,827 美元。

政府推動市場成長的舉措

近年來，由於世界各國政府的積極參與，全球多發性硬化症市場呈現成長態勢。政府正在積極採取多項措施來促進市場發展，包括促進行業的研究和開發、傳播對多發性硬化症的認識以及組織各種教育計劃。透過這些舉措，政府希望提高人們對該疾病的認識，增加患者獲得創新治療的機會，並改善衛生系統的基礎設施。這些努力對於推動市場成長和滿足未滿足的患者需求至關重要，同時培養創新解決方案以實現更好的疾病管理。

例如，著名的全國性非營利組織 MS Australia 讚揚了政府在 2024 年 5 月資助健康和醫學研究的承諾，但指出神經病學研究沒有獲得足夠的資金或對其沒有得到關注表示擔憂。該組織表示，像多發性硬化症（MS）這樣的神經系統疾病應該成為國家醫學研究的重點優先事項，並呼籲成立Neurological Research Mission。

技術進步推動市場

人工智慧的使用正在推動更先進、更有效的多發性硬化症治療方法的開發，也是推動全球多發性硬化症市場成長的主要因素。這些先進的儀器正在支持特定疾病藥物的開發，以幫助制定滿足每位患者需求的客製化治療計劃。人工智慧可以極大地幫助分析 MRI 掃瞄等放射影像，這對於診斷多發性硬化症至關重要。

本報告研究和分析了全球多發性硬化症市場，提供市場規模和預測、市場動態以及主要參與者的現狀和前景。

目錄

第1章 研究方法論

第2章 專案範圍與定義

第3章 執行摘要

第4章 全球多發性硬化症市場展望（2017-2031）

  • 市場規模及預測
    • 金額
    • 數量
  • 依 MS 類型
    • 臨床孤立症候群
    • 復發緩解型多發性硬化症
    • 繼發性進行性多發性硬化症
    • 原發性進行性多發性硬化症
  • 依藥物類別
    • 免疫調節
    • 免疫抑製劑
    • 干擾素
    • 其他
  • 透過診斷
    • 驗血
    • 脊椎穿刺
    • 核磁共振成像
    • 誘發電位測試
  • 依給藥途徑
    • 注射
    • 口服
  • 依最終用戶
    • 醫院
    • 專科診所
    • 居家護理
    • 其他
  • 依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 市場佔有率：依公司劃分（2023 年）

第5章 全球多發性硬化症市場展望：依地區（2017-2031）

  • 北美
    • 市場規模及預測
    • 依 MS 類型
    • 依藥物類別
    • 透過診斷
    • 依給藥途徑
    • 依最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 南美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第6章 市場測繪（2023）

  • 依 MS 類型
  • 依藥物類別
  • 透過診斷
  • 依給藥途徑
  • 依最終用戶
  • 依地區

第7章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第8章 市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第9章 監理架構與創新

  • 專利情況
  • 創新/新技術

第10章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT 分析（5 家市場公司）
  • 專利分析（如果適用）

第11章 價格分析

第12章 案例研究

第13章 主要公司展望

  • Biogen Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mylan NV

第14章 戰略建議

第15章 關於我們公司、免責聲明

Product Code: MX11505

Global multiple sclerosis market is projected to witness a CAGR of 4.24% during the forecast period 2024-2031, growing from USD 27.12 billion in 2023 to USD 37.81 billion in 2031. Various factors are shaping the global multiple sclerosis market, such as initiatives undertaken by the governments of different countries, technological advancements, increasing demand for immunosuppressant drugs, treatment of relapsing-remitting disease, and growing focus on research and development.

Governments across the world have been taking numerous initiatives to guide and educate people about the treatments used to manage multiple sclerosis and to promote public awareness of the disease. These initiatives help to speed up the expansion of the global multiple sclerosis market and support regional development. Tools based on artificial intelligence are increasingly being used and have disrupted the global multiple sclerosis market. These tools have transformed the global multiple sclerosis market by leading to changes in the development of novel medicines. There has been an increase in the research capacity, leading to the development of more advanced and precise drugs for treating multiple sclerosis.

The growth of global multiple sclerosis market is being influenced by the rising demand for immunosuppressant drugs for treating different types of multiple sclerosis. These medications alter the immune system's response and are responsible for reducing inflammation and slowing down the aging process. The global multiple sclerosis market is being driven by the increasing demand for the drugs available to treat relapsing-remitting multiple sclerosis. Various companies focus on developing customized treatments to fulfill the demand by addressing specific difficulties and symptoms associated with the disease. Key players in the global multiple sclerosis market prioritize improving the disease's progression by focusing on improving symptomatic management through research and development. These initiatives are bolstering the development of innovative technologies for disease management.

For instance, in May 2024, Alexander Gow, Ph.D., professor and associate director of the Center for Molecular Medicine and Genetics, as well as professor of pediatrics and neurology at Wayne State University School of Medicine, was granted USD 644,827 for three years by the NMSS (National Multiple Sclerosis Society) to find the possible causes of multiple sclerosis.

Government Initiatives to Drive the Market Growth

Lately, the global multiple sclerosis market has been observing growth due to the active involvement of governments across the world. Governments are proactively taking several steps to promote the development of the market, such as boosting research and development in the industry, spreading awareness about multiple sclerosis, and organizing various educational programs. Through these initiatives, the government wants to increase awareness about the disease and make innovative treatments accessible to patients while improving the healthcare system's infrastructure. Such initiatives aid in propelling market growth and are essential in meeting the patient's unmet needs while promoting innovative solutions for better disease management.

For instance, MS Australia, a prominent national non-profit organization, applauded the government's commitment to fund health and medical research in May 2024 but expressed concern that neurological research is not receiving enough funding or attention. The organization called for the creation of a Neurological Research Mission stated that neurological disorders such as multiple sclerosis (MS) should be a key national priority for medical research.

Technological Advancements to Facilitate the Market

The use of artificial intelligence is facilitating the development of more advanced and efficient treatments for multiple sclerosis, thus being a major factor driving the growth of the global multiple sclerosis market. These advanced instruments support the development of disease-specific medications that help create customized treatment plans that meet the requirements of every patient. AI can be highly useful in analyzing radiological images, such as magnetic resonance imaging (MRI) scans, which are essential in diagnosing multiple sclerosis.

For instance, in May 2024, Head Diagnostics (Dublin, Ireland) and the Royal College of Surgeons in Ireland collaborated on clinical research to improve the monitoring and assessment of Multiple Sclerosis (MS) using cutting-edge technologies. The study, which was started in conjunction with World MS Day, aims to provide more impartiality in the evaluation of the condition by investigating the application of novel digital biomarkers to monitor disease.

Increasing Demand for Immunosuppressant Drugs

Immunosuppressant drugs are excessively used globally as they tend to protect the myelin sheath from the harmful effects of the overactive immune system. These drugs suppress the immune system's reaction and reduce inflammation in the myelin sheath. Immunosuppressant drugs provide adequate results against the disease by prolonging the course of the disease. There has been a significant rise in demand for these drugs in the global multiple sclerosis market due to the rapid rise in the prevalence of the disease.

In February 2024, Roche Pharma introduced Ocrelizumab, sold under the brand name Ocrevus, in the Indian market for the management of multiple sclerosis and the slow progression of disability. Ocrevus is an immunosuppressant drug made from artificially produced antibodies obtained from human cells.

Treatment of Relapsing-Remitting MS

The increase in demand for drugs used to treat relapsing-remitting multiple sclerosis is a major factor driving the growth of the global multiple sclerosis market. Recently, several major companies have been making efforts to increase the efficiency of the drugs used to treat relapsing-remitting multiple sclerosis through improvements in drug research. Alternative treatment options are available to the patients through immunomodulators and immunosuppressants. These alternatives are highly efficient in treating disease as they can address the personalized requirements of patients. Pharmaceutical companies are expected to diverge their products related to RRMS (relapsing-remitting multiple sclerosis) due to the growing number of cases.

For instance, the U.S. Patent and Trademark Office (USPTO) granted a new patent covering the use of Ponvory (ponesimod), an oral medication approved for treating relapsing forms of multiple sclerosis (MS), spanning nearly two decades, according to a January 2024 announcement from Vanda Pharmaceuticals, a well-known international biopharmaceutical company. The recently granted patent particularly covers techniques for lowering clinical management events both before and during Ponvory treatment, as well as strategies for resuming medication following missing doses.

European Markets are Growing at a Fast Pace

Europe's multiple sclerosis market has observed significant changes. Companies focus on manufacturing new products through research and development, raising public knowledge of multiple sclerosis and its therapies. The global multiple sclerosis market participants focus on continuous clinical trials to improve the efficacy of the medications. The market is expanding due to pharmaceutical companies and concerned authorities meeting patient requirements, surpassing challenges such as diagnosis limitations.

For instance, in February 2024, Neuraxpharm Group, a European specialty pharmaceutical company focused on treating CNS disorders, announced the launch of BRIUMVI (ublituximab) in Europe. In adult patients, BRIUMVI is used for the treatment of relapsing multiple sclerosis with active disease. The drug was first launched in Germany and then in the rest of Europe.

Future Market Scenario (2024 - 2031F)

Cost-effective solutions such as biosimilars will reshape treatment options in the global multiple sclerosis market.

Advancements and growing demand for precision medicine will drive the need for personalized treatment options in the global multiple sclerosis market.

The integration of digital health solutions, such as telemedicine and remote monitoring, will influence the global multiple sclerosis market.

Increase in innovations in regenerative therapies offer promise for the treatment, boosting the growth of the global multiple sclerosis market.

Key Players Landscape and Outlook

Collaborations and partnerships have played an integral role in the growth of the global multiple sclerosis market. These collaborations ensure that different perspectives are considered to fulfill the diverse nature of the requirements. Pharmaceutical firms, healthcare providers, and government organizations are the major stakeholders in the market. The wide representation guarantees that different viewpoints are considered, resulting in more thorough and efficient solutions. Patient participation and engagement in the research process are prioritized in many collaborations. The method guarantees that therapies are customized to address the unique requirements and worries of individuals suffering from multiple sclerosis.

To operate and develop digital health solutions for rare diseases and neurological diseases such as multiple sclerosis, Aptar Digital Health, a division of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing, and protection technologies, entered into an enterprise agreement with Biogen Inc. in February 2024. Under the terms of the transaction, Biogen gave Aptar Digital Health (Aptar) ownership of several digital health products.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Multiple Sclerosis Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type of MS
    • 4.2.1. Clinically Isolated Syndrome
    • 4.2.2. Relapsing-remitting MS
    • 4.2.3. Secondary Progressive MS
    • 4.2.4. Primary Progressive MS
  • 4.3. By Drug Class
    • 4.3.1. Immunomodulatory
    • 4.3.2. Immunosuppressant
    • 4.3.3. Interferon
    • 4.3.4. Others
  • 4.4. By Diagnosis
    • 4.4.1. Blood Tests
    • 4.4.2. Spinal tap
    • 4.4.3. MRI
    • 4.4.4. Evoked Potential Tests
  • 4.5. By Route of Administration
    • 4.5.1. Injectable
    • 4.5.2. Oral
  • 4.6. By End-user
    • 4.6.1. Hospitals
    • 4.6.2. Specialty Clinics
    • 4.6.3. Homecare
    • 4.6.4. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. Asia-Pacific
    • 4.7.4. South America
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Multiple Sclerosis Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type of MS
      • 5.1.2.1. Clinically Isolated Syndrome
      • 5.1.2.2. Relapsing-remitting MS
      • 5.1.2.3. Secondary Progressive MS
      • 5.1.2.4. Primary Progressive MS
    • 5.1.3. By Drug Class
      • 5.1.3.1. Immunomodulatory
      • 5.1.3.2. Immunosuppressant
      • 5.1.3.3. Interferon
      • 5.1.3.4. Others
    • 5.1.4. By Diagnosis
      • 5.1.4.1. Blood Tests
      • 5.1.4.2. Spinal tap
      • 5.1.4.3. MRI
      • 5.1.4.4. Evoked Potential Tests
    • 5.1.5. By Route of Administration
      • 5.1.5.1. Injectable
      • 5.1.5.2. Oral
    • 5.1.6. By End-user
      • 5.1.6.1. Hospitals
      • 5.1.6.2. Specialty Clinics
      • 5.1.6.3. Homecare
      • 5.1.6.4. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
        • 5.1.7.1.1. By Value
        • 5.1.7.1.2. By Volume
      • 5.1.7.2. By Type of MS
        • 5.1.7.2.1. Clinically Isolated Syndrome
        • 5.1.7.2.2. Relapsing-remitting MS
        • 5.1.7.2.3. Secondary Progressive MS
        • 5.1.7.2.4. Primary Progressive MS
      • 5.1.7.3. By Drug Class
        • 5.1.7.3.1. Immunomodulatory
        • 5.1.7.3.2. Immunosuppressant
        • 5.1.7.3.3. Interferon
        • 5.1.7.3.4. Others
      • 5.1.7.4. By Diagnosis
        • 5.1.7.4.1. Blood Tests
        • 5.1.7.4.2. Spinal tap
        • 5.1.7.4.3. MRI
        • 5.1.7.4.4. Evoked Potential Tests
      • 5.1.7.5. By Route of Administration
        • 5.1.7.5.1. Injectable
        • 5.1.7.5.2. Oral
      • 5.1.7.6. By End-user
        • 5.1.7.6.1. Hospitals
        • 5.1.7.6.2. Specialty Clinics
        • 5.1.7.6.3. Homecare
        • 5.1.7.6.4. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type of MS
  • 6.2. By Drug Class
  • 6.3. By Diagnosis
  • 6.4. By Route of Administration
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Biogen Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Merck & Co. Inc.
  • 13.3. Novartis AG
  • 13.4. Pfizer, Inc.
  • 13.5. Sanofi SA
  • 13.6. Teva Pharmaceutical Industries Ltd
  • 13.7. Bristol-Myers Squibb Company
  • 13.8. F. Hoffmann-La Roche Ltd
  • 13.9. Johnson & Johnson
  • 13.10. Mylan NV

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 4. Global Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 5. Global Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 6. Global Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 7. Global Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Multiple Sclerosis Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 12. North America Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 13. North America Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 14. North America Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 15. North America Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 20. United States Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 21. United States Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 22. United States Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 23. United States Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 27. Canada Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 28. Canada Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 29. Canada Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 30. Canada Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 34. Mexico Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 35. Mexico Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 36. Mexico Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37. Mexico Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 41. Europe Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. Europe Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 43. Europe Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Europe Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 49. Germany Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 50. Germany Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 51. Germany Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 52. Germany Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 56. France Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. France Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 58. France Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 59. France Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 63. Italy Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 64. Italy Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 65. Italy Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 66. Italy Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 70. United Kingdom Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 71. United Kingdom Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 72. United Kingdom Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. United Kingdom Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 77. Russia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 78. Russia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 79. Russia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Russia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 84. Netherlands Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. Netherlands Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 86. Netherlands Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Netherlands Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 91. Spain Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 92. Spain Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 93. Spain Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Spain Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 98. Turkey Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 99. Turkey Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 100. Turkey Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 101. Turkey Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 105. Poland Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 106. Poland Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 107. Poland Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 108. Poland Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 112. South America Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 113. South America Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 114. South America Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. South America Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 120. Brazil Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 121. Brazil Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 122. Brazil Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 123. Brazil Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 127. Argentina Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 128. Argentina Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 129. Argentina Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. Argentina Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 134. Asia-Pacific Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Asia-Pacific Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 136. Asia-Pacific Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Asia- Pacific Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 139. India Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 142. India Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 143. India Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 144. India Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. India Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 149. China Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 150. China Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 151. China Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 152. China Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 156. Japan Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 157. Japan Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 158. Japan Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 159. Japan Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 163. Australia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 164. Australia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 165. Australia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. Australia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 170. Vietnam Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 171. Vietnam Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 172. Vietnam Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Vietnam Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 177. South Korea Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 178. South Korea Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 179. South Korea Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. South Korea Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 184. Indonesia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 185. Indonesia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 186. Indonesia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 187. Indonesia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 191. Philippines Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 192. Philippines Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 193. Philippines Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 194. Philippines Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 198. Middle East & Africa Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 199. Middle East & Africa Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 200. Middle East & Africa Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 201. Middle East & Africa Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 206. Saudi Arabia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 207. Saudi Arabia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 208. Saudi Arabia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 209. Saudi Arabia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 213. UAE Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 214. UAE Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 215. UAE Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 216. UAE Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 220. South Africa Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 221. South Africa Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 222. South Africa Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 223. South Africa Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Type of MS Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023